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INTRODUCTION
Three randomized trials indicate that circumcised men have lower risk of acquisition of human
immunodeficiency virus (HIV) than uncircumcised men,1-3 and prevention interventions
focusing on male circumcision (MC) are being introduced worldwide. Whether MC is
associated with women's risk of acquisition of HIV or other sexually transmitted infections
(STIs), however, has not been well-studied. (The only exception is women's risk of cervical
cancer – of which sexually transmitted human papillomavirus (HPV) is a necessary cause –
which is significantly lower in women with circumcised male partners.4) We found only two
studies describing the association between MC and women's risk of Neisseria gonorrhoeae
(GC), Chlamydia trachomatis (Ct), or Trichomonas vaginalis (Tv). In a large community
cohort study in Rakai, Uganda, women with circumcised partners had reduced Tv risk but equal
risks of GC and Ct when compared to women with uncircumcised partners.5 MC was strongly
associated with decreased odds of Ct seropositivity in female partners among controls recruited
for a case-control couples’ study of cervical cancer.6
MC could affect STI risk in women if it reduced men's risk of initial STI acquisition, and/or
subsequently decreased the probability of future STI transmission to susceptible female
partners. However, epidemiologic evidence regarding the association between MC and men's
risk of GC, Ct and Tv is mixed, and findings in several studies have been compromised by
small sample sizes, poor study designs, selection bias, uncontrolled confounding and other
validity concerns. For gonococcal infection, many studies found no association between MC
and men's GC risk,7-19 although circumcised men had lower GC risk in some.20-24 A
preponderance of evidence suggests no association between MC and men's infection with Ct
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8, 9, 11, 13-16, 18-21, 25-27 with few exceptions.22, 28 A recent meta-analysis of MC and men's
STI risk similarly concluded that there was no difference in men's risk of GC or Ct by
circumcision status.29 MC and Tv infection in men has not been investigated thoroughly. The
two existing studies (one cross-sectional30 and one ecologic18) both noted no association.
Because MC appears to be a promising disease prevention strategy, we analyzed whether MC
was associated with women's STI risk. Using data from a multi-site, prospective cohort study
conducted in Uganda, Zimbabwe and Thailand, we examined the effect of MC on women's
risk of acquisition of Ct, GC and Tv.
MATERIALS AND METHODS
The Hormonal Contraception and Risk of HIV Acquisition (HC-HIV) study is a prospective
cohort study with a primary objective to assess the effect of hormonal contraception on
women's risk of HIV acquisition. Detailed methods have been described elsewhere.31 We used
the HC-HIV data to evaluate the association between MC and women's STI risk.
Study setting and population
The HC-HIV study enrolled and followed women from 1999-2004. Eligible women were 18-35
years of age; HIV-negative; sexually active; not pregnant or planning a pregnancy; and using
oral contraceptive pills, injectable depot medroxyprogesterone acetate, or a non-hormonal or
no contraceptive method. Women were recruited from three sites in Kampala, Uganda; four
sites in Harare and Chitungwiza, Zimbabwe; and seven sites in Chiang Mai, Hat Yai, Khon
Kaen, and Bangkok, Thailand.
All Zimbabwean and most Ugandan and Thai participants were recruited from family planning
and maternal-child health (FP/MCH) clinics. Owing to low initial HIV incidence rates among
Ugandan and Thai women, recruitment in these countries was expanded to include referrals
from “higher-risk” populations, such as sexually transmitted disease clinics, sex workers and
military wives.
Data collection
Participants reported their reproductive and sexual behavior during face-to-face interviews
conducted at enrollment and during follow-up visits (every 3 months for approximately 24
months). Women also reported the circumcision status and other characteristics of their primary
partner. Each participant was asked at every visit whether she had the same primary partner as
at her previous visit; the circumcision status of any new primary partner was recorded.
At each visit we collected a single endocervical swab for polymerase chain reaction (PCR)
identification of both gonococcal and chlamydial infection (AMPLICOR® Ct/NG Test, Roche
Diagnostics, Somerville, NJ, USA). For Ct, optical density (OD) >0.8 was considered positive,
and for GC, OD>2.5 was positive. Negative results were indicated for OD <0.2 for both Ct
and GC. Testing was repeated if the results fell in the “gray zone” (for Ct: OD of 0.2–0.8; for
GC, OD of 0.2–2.5). Trichomonas vaginalis was diagnosed using wet mount with examination
under low (10×) and high (40-45×) magnification. Identification of motile flagellated
trichomonads indicated positive Tv infection.
Participants found to be Ct-infected at baseline or during follow-up were usually treated with
doxycycline (100 mg twice daily for 7 days, oral), though azithromycin (1 g, oral) was also
used occasionally in both Uganda and Thailand; pregnant women with Ct received
erythromycin (500 mg four times daily for 7 days, oral). Women with GC in Zimbabwe were
treated with kanamycin (2 g, intramuscular) or norfloxacin (800 mg, oral), whereas
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ciprofloxacin (400 mg, oral) was used in Uganda and ceftriaxone (125 mg, intramuscular) in
Thailand. Tv was treated with metronidazole (2 g, oral) in all three countries.
Statistical analyses
All statistical analyses were performed using SAS (Version 9.1.3, SAS Institute, Cary, NC).
We estimated unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs)
for the effect of primary partner's circumcision status on women's time to first infection with
1) Ct; 2) GC; 3) Tv; and 4) any STI (Ct, GC or Tv). We used extended Cox proportional hazards
models to account for both time-independent and time-varying covariates.32
Our outcome was the first incident infection with each of the STIs under investigation. An
infection was considered the first incident infection if the participant had tested negative for
that STI at all previous follow-up visits. Women testing positive at baseline were treated and
entered the at-risk pool for this analysis after receiving a negative result. Person-time preceding
a missing STI outcome was excluded.
We restricted the analysis to women who completed at least one follow-up visit with valid STI
results and non-missing MC status of the primary sexual partner. Because of HC-HIV's primary
objective, women's follow-up time was censored at the visit they were found to be HIV-
infected; women who used exclusively non-study contraceptive methods for their full follow-
up were also excluded. Follow-up was scheduled to end at 24 months, but a small group of
participants returned for their final visit much later. For these women (n=101) we censored
follow-up time after 28 months.
The HC-HIV study enrolled 6,109 participants. For these analyses, we excluded 184 women:
149 never returned after enrollment; 9 returned for the first time after 28 months; 12 were
missing the circumcision status of their primary partner at every follow-up visit; and 14 were
missing results for Ct, GC and Tv at every follow-up visit. We separately analyzed each
outcome from this starting pool of 5,925 women. Person-time contributed by women remaining
infection-free for the full study duration was calculated as the number of months from
enrollment to the last study visit. For women who acquired an STI during follow-up, person-
time was calculated as the time from enrollment to first infection with the specific STI under
investigation. For the combined analysis of all three STIs, women were censored after their
first diagnosis with any one of the three infections.
Multivariable models were constructed as described elsewhere.33 Briefly, we examined
participants’ demographic characteristics, reproductive factors and sexual behavior; we
included in preliminary multivariable models all variables associated with MC or incident STI.
We evaluated the proportional hazards assumption (PHA) using Cox tests and through visual
inspection of log -log plots.34 For any variable violating the PHA, we created product-
interaction variables with time to include in preliminary multivariable models.
To construct final models, we used a manual, backward elimination, change-in-estimate
strategy.35 One at a time, we removed covariates from the preliminary, full model; if removal
changed the MC-STI association by less than 10% overall or in any stratum of any interacting
variable, a given covariate was not retained. We designated models as “final” when the
remaining covariates confounded the MC-STI association or were retained for a priori
considerations (age and contraceptive method).
Any covariate surviving the manual backward elimination procedure for at least one of the four
MC-STI associations was included in the adjustment set for all other analyses.
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Missing data—Fifty-six women (0.9%) were missing the circumcision status of their primary
partners at baseline, but subsequently provided this information during follow-up. These
women are excluded from descriptions of participant characteristics by baseline male
circumcision status but included in multivariate models, which permit partner circumcision
status to change if women change primary partners.
At any follow-up visit, women missing Ct, GC or Tv results were coded as missing for the
“any STI” analysis. Therefore, more women and more follow-up time are included in analyses
of individual STIs than in the analysis of the three infections combined.
Sensitivity analysis
Our main analyses evaluated the effect of circumcision status of the primary partner on
women's risk of acquisition of three STIs. Because some women reported multiple sexual
partnerships during follow-up, our observed associations may reflect a mixture of the effects
of primary and non-primary partners’ circumcision status. We conducted a simple sensitivity
analysis by removing from the analysis all follow-up time where women reported multiple
sexual partners. We then refit the unadjusted and adjusted models (using the same set of
adjustment variables as in the main analysis) to determine whether the associations between
MC and women's STI risk changed.
Ethical approval
All women enrolled in the HC-HIV study gave written informed consent prior to participating,
and ethics committees at collaborating institutions gave approval for the study. The




The study population was comprised of women from Uganda (36.8%), Zimbabwe (37.6%) and
Thailand (25.6%). High-risk participants from Uganda and Thailand made up 14.2% of the
overall cohort (Table 1).
At baseline, 18.6% of participants reported a circumcised primary partner, 70.8% had an
uncircumcised partner, and 9.7% said they did not know whether their partner was circumcised
(Table 1). Circumcision was more common among partners of Ugandan women (35.7%) than
among partners of women from Zimbabwe (9.4%) or Thailand (7.4%). Although the
circumcision prevalence varied substantially by country, it did not vary by referral population
within Uganda or Thailand. Of 575 participants reporting that they did not know whether their
primary partners were circumcised, 409 (71.1%) were Thai, 163 (28.3%) were Zimbabwean
and 3 (0.5%) were Ugandan. Participants’ age did not vary substantially by circumcision status
(median: 25 years for women with circumcised and uncircumcised partners and 26 years among
women who did not know whether their partners were circumcised). The median level of
education for all women, regardless of partner circumcision status, was 9 years. Most women
(87.2%) cohabitated with their primary partner.
Women with circumcised partners reported somewhat riskier sexual behavior at baseline than
women with uncircumcised partners or those who did not know whether their partners were
circumcised. Participants with circumcised partners had a lower median age at coital debut (17
years vs. 18 for women with uncircumcised partners and 19 for women who did not know their
partners’ circumcision status). Although the median number of sex partners in the last 3 months
was the same for all groups (1 partner), women with circumcised partners had a higher mean
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number of partners (1.9 vs. 1.3 and 1.5 partners for women with uncircumcised partners and
partners of unknown circumcision status, respectively). Similarly, each group reported a
median of 0 nights that the primary partner was away from home in the last month, but women
with circumcised partners had a higher mean number of nights when the partner was away
(mean: 8.7 nights vs. 5.4 nights for women with uncircumcised partners and 3.8 nights for
women who did not know whether their partners were circumcised). The majority of women
(71.7% overall) reported ever using male condoms, including a higher proportion of women
with circumcised partners (78.0%) than uncircumcised partners (71.5%). Fewer women who
did not know whether their partner was circumcised reported ever using male condoms
(58.1%).
Prevalent STI at baseline was relatively rare (Table 1), and did not vary substantially by
baseline MC status of the primary partner. At the enrollment visit, 3.5% of participants were
diagnosed with Ct (3.7%, 3.2% and 5.4% of women with partners who were circumcised,
uncircumcised, and of unknown circumcision status, respectively), 1.6% with GC (2.3%, 1.5%
and 1.2%, respectively), and 2.6% with Tv (2.5%, 2.7% and 2.1%, respectively).
Unadjusted and adjusted multivariable models
Chlamydial infection—Ct was the most common incident STI in this cohort, with 408
women acquiring a new Ct infection during follow-up. The unadjusted incidence rate (IR)
among women with circumcised partners was 4.5/100 person-years (PY), compared to 3.9/100
PY for participants with uncircumcised partners and 5.1/100 PY among those who did not
know whether their partners were circumcised (Table 2).
Time to Ct infection was similar for women with circumcised vs. uncircumcised partners After
adjustment for contraceptive method, age, age at coital debut, and country, the adjusted HR
was 1.25 (95% CI: 0.96 to 1.63) (Table 3).
Gonococcal infection—The unadjusted IR for GC among participants with circumcised
primary partners was 3.8/100 PY, compared to 3.0/100 PY for those with uncircumcised
partners and 1.7/100 PY for women whose partners’ circumcision status was unknown (Table
2).
The adjusted HR comparing time to initial GC for women with circumcised partners to those
with uncircumcised partners was 0.99 (95% CI: 0.74 to 1.31) (Table 3).
Trichomonal infection—The unadjusted IRs for T. vaginalis were 4.5/100 PY for women
reporting circumcised primary partners, 3.8/100 PY for participants with uncircumcised
partners, and 1.2/100 PY for women who did not know whether their partners were circumcised
(Table 2).
The adjusted HR for Tv comparing women with circumcised partners to those with
uncircumcised partners was 1.05, 95% CI: 0.80 to 1.36) (Table 3).
Any STI: Ct, GC or Tv—Ct, GC or Tv was diagnosed in 887 women over the follow-up
period: women with circumcised partners had an IR of 10.3/100 PY; participants with
uncircumcised partners had an IR of 9.5/100 PY; and women who did not know whether their
partners were circumcised had an IR of 7.2/100 PY (Table 2).
The adjusted HR comparing time to initial STI for women with circumcised vs. uncircumcised
partners was 1.02 (95% CI: 0.85 to 1.21) (Table 3).
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Modeling results were largely unchanged when examining baseline (rather than time-varying)
partner circumcision status. Because baseline condom use and baseline prevalence of GC and
Tv was lower among Thai participants, we also examined whether restricting the analysis
population to only African women affected our results; effect estimates were largely unchanged
(data not shown).
Sensitivity analysis
When we excluded follow-up time where women reported multiple partnerships, our restricted
datasets contained approximately 2.5% fewer person-years of follow-up. After restriction,
nearly all effect estimates were unchanged (data not shown). The HRs for Ct, however,
strengthened somewhat, particularly in the adjusted model (restricted HR: 1.37, 95% CI: 1.04
to 1.80).
DISCUSSION
In both unadjusted and adjusted analyses, women with circumcised partners had similar risk
of chlamydial, gonococcal and trichomonal infections as women with uncircumcised partners.
Our findings largely agree with prior studies on MC and men's risk of these STIs. The literature
on men's risk of Ct and Tv suggests no protective effect of circumcision (although the few
studies of MC and Tv make overall conclusions difficult). Although the literature on MC and
men's risk of GC is mixed, most reports suggest that MC is not associated with men's GC risk.
At least two mechanisms exist by which MC could affect women's STI risk. First, MC may
change men's STI risk, and subsequently alter the probability that women will be exposed to
infected men. However, as described above, no strong evidence supports a conclusively
protective role for MC against men's acquisition of the three STIs evaluated here. Second, MC
may change the probability of transmission from infected men to susceptible women - the
absence of a foreskin may alter the efficiency of pathogen transmission. Although Ct, GC and
Tv infections in men occur nearly exclusively in the urethra,36 the foreskin is a repository for
shed cells and secretions, and a moist, hospitable environment for pathogen growth. STI-
infected, uncircumcised men may therefore expose their female partners to a higher pathogen
burden than STI-infected circumcised men. Transient infectious organisms that do not
ultimately adhere and infect exposed men may also have longer viability in uncircumcised
men. We found no reports comparing pathogen burdens in circumcised vs. uncircumcised men.
Three clinical trials found a strong protective effect of MC against men's risk of HIV
acquisition.1-3 More than 50 cohort and cross-sectional studies found largely similar results.
Few prospective evaluations have characterized the effect of MC on women's HIV risk, and
the small number of existing studies have had mixed findings: an analysis of these HC-HIV
data found no effect of MC on women's HIV risk in women from FP/MCH populations,33
whereas three other prospective studies determined that women with circumcised partners had
lower HIV risk than women with uncircumcised partners (in Tanzania37 and Uganda13, 38). A
more recent evaluation in Rakai, Uganda found reduced, but non-significant, reductions in HIV
risk for women with circumcised partners.5
Our analysis has a number of limitations. First, because this is a secondary data analysis, some
variables that may have contributed to the analysis were unmeasured (e.g., potential
confounders including women's or partners’ religion).39 In addition, an evaluation of MC and
women's risk of syphilis or chancroid might have been informative, since MC has been
associated with reduced risk of these two infections in men.40 Unfortunately, we did not have
incidence data on syphilis or chancroid in our cohort.
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Second, women's sexual behavior, as well as MC, were self-reported, and may suffer from
recall and social desirability biases. Misclassification of self-reported MC particularly has been
noted as a limitation in previous studies,39, 41 and several have attempted to characterize the
accuracy with which men and their female partners can classify circumcision.4, 16, 20, 21, 25,
42-50 If MC misclassification exists and is nondifferential (not associated with STI status), the
observed effect of MC will be biased toward the null. In a previous analysis, using three data-
driven scenarios (R. Gray, unpublished data)48, 50 we examined the effect of MC
misclassification on the observed association between MC and women's risk of HIV
acquisition;33 that sensitivity analysis resulted in little change in our findings for MC and
women's HIV risk.33 We expect bias to be similarly minimal in these analyses of women's STI
risk.
We saw further evidence against MC misclassification when examining data from various
sources, including the Demographic and Health surveys (DHS),51-53 reporting that
circumcision prevalence in Uganda is 25%, Zimbabwe is 10% and Thailand is 7%. Our
measured MC prevalences in Zimbabwe (9%) and Thailand (7%) match the DHS estimates,
but our estimate for Uganda (36%) is higher than expected given the DHS finding of 25%.
This may be evidence of misclassification, though if women were uncertain, we expect that
more of them would have reported not knowing their partners’ circumcision status. Instead,
only three participants in Uganda reported a partner with unknown MC status, compared to
163 in Zimbabwe and 409 in Thailand. The higher observed MC prevalence in Uganda may
also be evidence of selection issues (e.g., a higher than expected proportion of participants with
Muslim partners) which could further be associated with behavioral differences; as indicated
above, we did not collect data on women's or partner's religion, so we cannot explore this
possible confounder. Finally, we note that in societies where MC is not traditionally practiced,
men who seek out circumcision may do so to relieve genitourinary problems (e.g., recurrent
STIs or balanitis). Because we did not have information on women's partners’ age at or reason
for circumcision, we could not identify which partners chose circumcision for these reasons.
These men may be at higher STI risk, and analyzing them in the same category as other
circumcised men may have skewed the observed MC-STI associations.
We also did not know the STI status of women's partners. This information would have
permitted various other informative analyses, including separate characterization of the effect
of MC on men's initial STI risk and the effect of MC on the STI transmissibility from infected
men to susceptible women. Instead, our measures of effect capture the overall, combined effect
of these two pathways. In addition, the impact of MC on reducing STI transmission from men
to women could be different by men's HIV status, if HIV-infected men had more frequent or
severe episodes of STI, yet the HIV status of women's partners was also unmeasured.
As with any laboratory procedure, methods to diagnose Ct, GC and Tv are not always accurate.
Microscopy (wet mount), the diagnostic method for trichomonas, has poor sensitivity
(49%-67%) but nearly perfect specificity (often cited as 100%) compared to PCR.54-57 A
substudy conducted just among Zimbabwean participants at selected visits, which assessed Tv
as a risk factor for HIV acquisition, compared wet mount with PCR for Tv diagnosis. This
investigation concluded that the sensitivity and specificity for Tv diagnosis by microscopy was
similar to published reports.58 We anticipate that misclassification of Tv status would be
nondifferential (not associated with MC), suggesting that the observed effect estimates may
be biased toward the null. The AMPLICOR® CT/NG test, which has published sensitivity and
specificity of 91.7% and 99.7%, respectively, for Ct59 and 92.4% and 99.5%, respectively, for
GC,60 has been criticized for cross-reactivity with nonpathogenic neisseriae strains,61-63
leading to higher false-positive rates than test characteristics would indicate. False-positive
results are an issue of particular importance in a low-prevalence setting such as ours. In light
of this problem, our outcome classification used the adjusted optical density parameters
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described in the methods (B. Van der Pol, personal communication), but some women
diagnosed with GC during follow-up may have been misclassified.
Because our main analysis evaluated only MC status of women's primary partner, for women
with multiple partners, the observed associations mix the effect of MC status of primary and
non-primary partners. To address this limitation we included a sensitivity analysis that
excluded follow-up time where women reported multiple partnerships; this analysis confirmed
a lack of association between MC and GC or Tv. However, in adjusted models, monogamous
women with circumcised partners appeared to have a significantly increased risk of incident
chlamydial infection compared to women with uncircumcised partners.
This finding disagrees with the only existing study of MC and women's Ct risk (Castellsague
et al.),6 which found significant protection against Ct seropositivity for women with
circumcised partners (OR: 0.18, 95% CI: 0.05-0.58). However, both our study and that by
Castellsague et al. were secondary data analyses using information originally captured to
answer a different research question, and there are substantial differences between the two
analyses that could have led to the contradicting results. These include design (prospective
cohort vs. cross-sectional study), population (FP/MCH clinic attendees with a small proportion
of higher-risk participants vs. general population and hospital-based controls recruited for a
case-control study of cervical cancer in Colombia, Spain, Brazil, Thailand and the Philippines),
total sample size (n=5,925 vs. n=300), number of Ct cases (n=408 vs. n=84) and method of
outcome detection (PCR vs. microimmunofluorescence detection of Ct antibodies). Of note,
when the data from Castellsague et al. are analyzed by individual country, the protective
association between MC and Ct persists but is no longer statistically significant (Thailand, OR:
0.28, 95% CI: 0.03-2.99; Philippines, OR: 0.21, 95% CI: 0.04-1.21; presumably because of
small cell sizes, individual ORs not calculated for Colombia, Spain and Brazil).6
MC has the potential to reduce HIV risk among millions of men, and intervention programs
are being planned worldwide. The effect of MC on men's STI risk is not yet clear, and further
research is warranted to determine whether MC also has direct or indirect effects on women's
STI risk.
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TABLE 1




Country and referral population
    Uganda
        Family planning/maternal-child health clinics 1790 30.2
        STD clinics, military wives, sex worker networks 390 6.6
    Thailand
        Family planning/maternal-child health clinics 1065 18.0
        STD clinics, military wives, sex worker networks 452 7.6
    Zimbabwe 2228 37.6
Baseline circumcision status of the primary partner
    Circumcised 1100 18.6
    Uncircumcised 4194 70.8
    Don't know 575 9.7
    Missing 56 0.9
Baseline contraceptive method
    Combined oral contraceptive pills 2003 33.8
    Injectable depot medroxyprogesterone acetate 2075 35.0
    Non-hormonal or no contraceptive method 1847 31.2
CT status at enrollment
    Positive 208 3.5
    Negative 5645 95.3
    Indeterminate 22 0.4
    Missing 50 0.8
GC status at enrollment
    Positive 96 1.6
    Negative 5757 97.2
    Indeterminate 23 0.4
    Missing 49 0.8
TV status at enrollment
    Positive 152 2.6
    Negative 5766 97.3
    Not done 7 0.1
Currently cohabitate with primary partner
    Yes 5169 87.2
    No 756 12.8
Currently employed
    Yes 3382 57.1
    No 2543 42.9
Husband currently employed
    Yes 5671 95.7

















    No 201 3.4
    Missing 53 0.9
Male condom use ever
    Yes 4246 71.7
    No 1678 28.3
    Don't know 1 0.02
Sex with men other than primary partner in last 3 months
    Yes 275 4.6
    No 5649 95.3
    Missing 1 0.02
Sex while intoxicated in last 3 months
    Yes 522 8.8
    No 5402 91.2
    Don't know 1 0.02
Ever exchanged sex for money or goods
    Yes 181 3.0
    No 5744 97.0
Median IQR*
Age (years) 25 22 to 29
Education (years) 9 7 to 11
Age at coital debut (years) 18 16 to 19
Age of primary partner (years) 30 27 to 35
Number of pregnancies 2 1 to 3
Number of sex partners, last three months 1 1 to 1
Number sex acts in last 30 days with primary partner 9 4 to 16
Nights primary partner away in last 30 days 0 0 to 7
*
IQR = interquartile range
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TABLE 3
Unadjusted and adjusted hazard ratios and 95% confidence intervals comparing STI risk for women with
circumcised vs. uncircumcised primary partners.
Outcome Events HR (95% CI)
Ct
    Unadjusted 408 1.14 (0.89, 1.45)
    Adjusted* 408 1.25 (0.96, 1.63)
GC
    Unadjusted 305 1.24 (0.95, 1.63)
    Adjusted* 305 0.99 (0.74, 1.31)
Tv
    Unadjusted 362 1.19 (0.93, 1.53)
    Adjusted* 359 1.05 (0.80, 1.36)
Any STI
    Unadjusted 887 1.09 (0.92, 1.29)
    Adjusted* 884 1.02 (0.85, 1.21)
*
All adjusted models control for contraceptive method, age, age at coital debut, and country
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